Identification of novel omega-3 fatty acid-derived bioactive metabolites based on a targeted lipidomics approach

Journal of Clinical Biochemistry and Nutrition

Volumn 55, Issue 2, 2014, Pages 79-84

  Isobe, Yosuke ^a   Arita, Makoto ^a,b,c  

^a Institute of Physical and Chemical Research   (Japan)

^b YOKOHAMA CITY UNIVERSITY   (Japan)

^c JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

Author keywords

Anti inflammation; Lipid mediator; Metabolomics; Omega 3 fatty acid

Indexed keywords

ANTIINFLAMMATORY AGENT; DOCOSAHEXAENOIC ACID; ICOSAPENTAENOIC ACID; OMEGA 3 FATTY ACID; RESOLVIN E1; RESOLVIN E2; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; DIASTEREOISOMER; DIET SUPPLEMENTATION; EOSINOPHIL; EPOXYGENATION; HUMAN; INFLAMMATION; ISOMER; LIPID METABOLISM; LIPIDOMICS; LIQUID CHROMATOGRAPHY; MEDIATOR; MEDIATOR RELEASE; NEUTROPHIL; NEUTROPHIL CHEMOTAXIS; NONHUMAN; REVIEW; STRUCTURE ACTIVITY RELATION; TANDEM MASS SPECTROMETRY;

EID: 84908506234     PISSN: 09120009     EISSN: None     Source Type: Journal    
DOI: 10.3164/jcbn.14-18     Document Type: Review

References (29)

1. De Caterina R, Endres S, Kristensen SD, Schmidt EB, eds. n-3 Fatty Acids and Vascular Disease. London: Springer-Verlag, 1993.
2. Simopoulos AP. Omega-3 fatty acids in inflammation and autoimmune diseases. J Am Coll Nutr 2002; 21: 495-505.
3. Kang JX, Wang J, Wu L, Kang ZB. Transgenic mice: fat-1 mice convert n-6 to n-3 fatty acids. Nature 2004; 427: 504.
4. Kang JX. Fat-1 transgenic mice: a new model for omega-3 research. Prostaglandins Leukot Eessent Fatty Acids 2007; 77: 263-267.
5. Schmitz G, Ecker J. The opposing effects of n-3 and n-6 fatty acids. Prog Lipid Res 2008; 47: 147-155.
6. Serhan CN. Resolution phase of inflammation: novel endogenous antiinflammatory and proresolving lipid mediators and pathways. Annu Rev Immunol 2007; 25: 101-137.
7. Bannenberg G, Serhan CN. Specialized pro-resolving lipid mediators in the inflammatory response: an update. Biochim Biophys Acta 2010; 1801: 1260-1273.
8. Haworth O, Cernadas M, Yang R, Serhan CN, Levy BD. Resolvin E1 regulates interleukin 23, interferon-gamma and lipoxin A4 to promote the resolution of allergic airway inflammation. Nat Immunol 2008; 9: 873-879.
9. Aoki H, Hisada T, Ishizuka T, et al. Resolvin E1 dampens airway inflammation and hyperresponsiveness in a murine model of asthma. Biochem Biophys Res Commun 2008; 367: 509-515.
10. Xu ZZ, Zhang L, Liu T, et al. Resolvins RvE1 and RvD1 attenuate inflammatory pain via central and peripheral actions. Nat Med 2010; 16: 592-597.
11. Bohr S, Patel SJ, Sarin D, Irimia D, Yarmush ML, Berthiaume F. Resolvin D2 prevents secondary thrombosis and necrosis in a mouse burn wound model. Wound Repair Regen 2013; 21: 35-43.
12. Arita M, Yoshida M, Hong S, et al. Resolvin E1, an endogenous lipid mediator derived from omega-3 eicosapentaenoic acid, protects against 2,4,6-trinitrobenzene sulfonic acid-induced colitis. Proc Natl Acad Sci U S A 2005; 102: 7671-7676.
13. Spite M, Norling LV, Summers L, et al. Resolvin D2 is a potent regulator of leukocytes and controls microbial sepsis. Nature 2009; 461: 1287-1291.
14. Chiang N, Fredman G, Bäckhed F, et al. Infection regulates pro-resolving mediators that lower antibiotic requirements. Nature 2012; 484: 524-528.
15. Arita M, Bianchini F, Aliberti J, et al. Stereochemical assignment, antiinflammatory properties, and receptor for the omega-3 lipid mediator resolvin E1. J Exp Med 2005; 201: 713-722.
16. Oh SF, Pillai PS, Recchiuti A, Yang R, Serhan CN. Pro-resolving actions and stereoselective biosynthesis of 18S E-series resolvins in human leukocytes and murine inflammation. J Clin Invest 2011; 121: 569-581.
17. Mas E, Croft KD, Zahra P, Barden A, Mori TA. Resolvins D1, D2, and other mediators of self-limited resolution of inflammation in human blood following n-3 fatty acid supplementation. Clin Chem 2012; 58: 1476-1484.
18. Arita M. Mediator lipidomics in acute inflammation and resolution. J Biochem 2012; 152: 313-319.
19. Serhan CN, Clish CB, Brannon J, Colgan SP, Chiang N, Gronert K. Novel functional sets of lipid-derived mediators with anti-inflammatory actions generated from omega-3 fatty acids via cyclooxygenase 2-nonsteroidal antiinflammatory drugs and transcellular processing. J Exp Med 2000; 192: 1197-1204.
20. Tjonahen E, Oh SF, Siegelman J, et al. Resolvin E2: identification and antiinflammatory actions: pivotal role of human 5-lipoxygenase in resolvin E series biosynthesis. Chem Biol 2006; 13: 1193-1202.
21. Isobe Y, Arita M, Matsueda S, et al. Identification and structure determination of novel anti-inflammatory mediator resolvin E3, 17,18-dihydroxyeicosapentaenoic acid. J Biol Chem 2012; 287: 10525-10534.
22. Yamashita A, Kawana K, Tomio K, et al. Increased tissue levels of omega-3 polyunsaturated fatty acids prevents pathological preterm birth. Sci Rep 2013; 3: 3113.
23. Urabe D, Todoroki H, Masuda K, Inoue M. Total syntheses of four possible stereoisomers of resolvin E3. Tetrahedron 2012; 68: 3210-3219.
24. Isobe Y, Arita M, Iwamoto R, et al. Stereochemical assignment and antiinflammatory properties of the omega-3 lipid mediator resolvin E3. J Biochem 2013; 153: 355-360.
25. Kubota T, Arita M, Isobe Y, et al. Eicosapentaenoic acid is converted via ω-3 epoxygenation to the anti-inflammatory metabolite 12-hydroxy-17,18-epoxyeicosatetraenoic acid. FASEB J 2014; 28: 586-593.
26. Arita M, Clish CB, Serhan CN. The contributions of aspirin and microbial oxygenase to the biosynthesis of anti-inflammatory resolvins: novel oxygenase products from omega-3 polyunsaturated fatty acids. Biochem Biophys Res Commun 2005; 338: 149-157.
27. Schwarz D, Kisselev P, Ericksen SS, et al. Arachidonic and eicosapentaenoic acid metabolism by human CYP1A1: highly stereoselective formation of 17(R),18(S)-epoxyeicosatetraenoic acid. Biochem Pharmacol 2004; 67: 1445-1457.
28. Lucas D, Goulitquer S, Marienhagen J, et al. Stereoselective epoxidation of the last double bond of polyunsaturated fatty acids by human cytochromes P450. J Lipid Res 2010; 51: 1125-1133.
29. Arnold C, Markovic M, Blossey K, et al. Arachidonic acid-metabolizing cytochrome p450 enzymes are targets of ω-3 fatty acids. J Biol Chem 2010; 285: 32720-32733.